% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kim:267562,
      author       = {J.-Y. Kim$^*$ and S. Zschaeck and J. Debus$^*$ and F.
                      Weykamp$^*$},
      title        = {{C}ombined {H}yperthermia and {R}e-{I}rradiation in
                      {N}on-{B}reast {C}ancer {P}atients: {A} {S}ystematic
                      {R}eview.},
      journal      = {Cancers},
      volume       = {15},
      number       = {3},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2023-00340},
      pages        = {742},
      year         = {2023},
      note         = {#EA:E050#LA:E050#},
      abstract     = {This systematic literature review summarizes clinical
                      studies and trials involving combined non-ablative
                      hyperthermia and re-irradiation in locoregionally recurrent
                      cancer except breast cancer.One database and one registry,
                      MEDLINE and clinicaltrials.gov, respectively, were searched
                      for studies on combined non-ablative hyperthermia and
                      re-irradiation in non-breast cancer patients. Extracted
                      study characteristics included treatment modalities and
                      re-irradiation dose concepts. Outcomes of interest were
                      tumor response, survival measures, toxicity data and
                      palliation. Within-study bias assessment included the
                      identification of conflict of interest (COI). The final
                      search was performed on 29 August 2022.Twenty-three articles
                      were included in the final analysis, reporting on 603
                      patients with eight major tumor types. Twelve articles
                      $(52\%)$ were retrospective studies. Only one randomized
                      trial was identified. No COI statement was declared in 11
                      studies. Four of the remaining twelve studies exhibited
                      significant COI. Low study and patient numbers, high
                      heterogeneity in treatment modalities and endpoints, as well
                      as significant within- and across-study bias impeded the
                      synthesis of results.Outside of locoregionally recurrent
                      breast cancer, the role of combined moderate hyperthermia
                      and re-irradiation can so far not be established. This
                      review underscores the necessity for more clinical trials to
                      generate higher levels of clinical evidence for combined
                      re-irradiation and hyperthermia.},
      subtyp        = {Review Article},
      keywords     = {hyperthermia (Other) / re-irradiation (Other)},
      cin          = {E050 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)E050-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {315 - Bildgebung und Radioonkologie (POF4-315)},
      pid          = {G:(DE-HGF)POF4-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36765699},
      doi          = {10.3390/cancers15030742},
      url          = {https://inrepo02.dkfz.de/record/267562},
}